Gossamer Bio, Inc. (NASDAQ:GOSS - Get Free Report) was the recipient of a large drop in short interest in September. As of September 15th, there was short interest totalling 8,550,000 shares, a drop of 5.8% from the August 31st total of 9,080,000 shares. Based on an average daily volume of 1,520,000 shares, the days-to-cover ratio is presently 5.6 days.
Shares of GOSS traded up $0.03 during trading hours on Monday, hitting $0.99. The stock had a trading volume of 149,034 shares, compared to its average volume of 1,535,027. Gossamer Bio has a 12-month low of $0.45 and a 12-month high of $1.60. The firm has a market cap of $224.50 million, a P/E ratio of -0.91 and a beta of 1.95. The company has a debt-to-equity ratio of 2.42, a quick ratio of 8.21 and a current ratio of 8.21. The company's fifty day simple moving average is $0.92 and its 200 day simple moving average is $0.89.
Gossamer Bio (NASDAQ:GOSS - Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.23 by ($0.01). The firm had revenue of $95.84 million during the quarter, compared to analyst estimates of $160.00 million. Equities research analysts forecast that Gossamer Bio will post -0.33 EPS for the current fiscal year.
Several equities analysts recently issued reports on GOSS shares. HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Gossamer Bio in a research note on Tuesday, September 17th. Wedbush reaffirmed an "outperform" rating and issued a $4.00 price objective on shares of Gossamer Bio in a research report on Tuesday, August 13th. The Goldman Sachs Group reiterated a "buy" rating and set a $8.00 target price on shares of Gossamer Bio in a research report on Monday, June 17th. Finally, Oppenheimer started coverage on Gossamer Bio in a report on Tuesday, June 25th. They issued an "outperform" rating and a $9.00 price target for the company. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Gossamer Bio currently has a consensus rating of "Buy" and a consensus target price of $9.20.
Get Our Latest Analysis on GOSS
Several institutional investors have recently bought and sold shares of the business. Algert Global LLC purchased a new position in shares of Gossamer Bio in the 2nd quarter valued at $75,000. The Manufacturers Life Insurance Company increased its holdings in Gossamer Bio by 67.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 310,213 shares of the company's stock valued at $279,000 after purchasing an additional 124,913 shares in the last quarter. NEA Management Company LLC raised its position in Gossamer Bio by 14.2% in the second quarter. NEA Management Company LLC now owns 18,093,034 shares of the company's stock valued at $16,300,000 after purchasing an additional 2,255,025 shares during the period. Marshall Wace LLP lifted its stake in shares of Gossamer Bio by 170.8% during the second quarter. Marshall Wace LLP now owns 3,335,511 shares of the company's stock worth $3,002,000 after purchasing an additional 2,103,766 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Gossamer Bio by 204.7% in the second quarter. Renaissance Technologies LLC now owns 2,046,600 shares of the company's stock worth $1,844,000 after buying an additional 1,375,000 shares during the period. 81.23% of the stock is currently owned by hedge funds and other institutional investors.
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gossamer Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gossamer Bio wasn't on the list.
While Gossamer Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.